These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 27419146)

  • 1. Overcoming the Constraints of Anti-HIV/CD89 Bispecific Antibodies That Limit Viral Inhibition.
    Yu X; Duval M; Gawron M; Posner MR; Cavacini LA
    J Immunol Res; 2016; 2016():9425172. PubMed ID: 27419146
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A bispecific antibody composed of a nonneutralizing antibody to the gp41 immunodominant region and an anti-CD89 antibody directs broad human immunodeficiency virus destruction by neutrophils.
    Duval M; Posner MR; Cavacini LA
    J Virol; 2008 May; 82(9):4671-4. PubMed ID: 18272577
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A recombinant bispecific single-chain fragment variable specific for HLA class II and Fc alpha RI (CD89) recruits polymorphonuclear neutrophils for efficient lysis of malignant B lymphoid cells.
    Guettinger Y; Barbin K; Peipp M; Bruenke J; Dechant M; Horner H; Thierschmidt D; Valerius T; Repp R; Fey GH; Stockmeyer B
    J Immunol; 2010 Feb; 184(3):1210-7. PubMed ID: 20042573
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antibody-dependent cellular cytotoxicity and neutralization of human immunodeficiency virus type 1 by high affinity cross-linking of gp41 to human macrophage Fc IgG receptor using bispecific antibody.
    Mabondzo A; Boussin F; Raoul H; Le Naour R; Gras G; Vaslin B; Bartholeyns J; Romet-Lemonne JL; Dormont D
    J Gen Virol; 1994 Jun; 75 ( Pt 6)():1451-6. PubMed ID: 8207409
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A tetravalent bispecific TandAb (CD19/CD3), AFM11, efficiently recruits T cells for the potent lysis of CD19(+) tumor cells.
    Reusch U; Duell J; Ellwanger K; Herbrecht C; Knackmuss SH; Fucek I; Eser M; McAleese F; Molkenthin V; Gall FL; Topp M; Little M; Zhukovsky EA
    MAbs; 2015; 7(3):584-604. PubMed ID: 25875246
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fab-based bispecific antibody formats with robust biophysical properties and biological activity.
    Wu X; Sereno AJ; Huang F; Lewis SM; Lieu RL; Weldon C; Torres C; Fine C; Batt MA; Fitchett JR; Glasebrook AL; Kuhlman B; Demarest SJ
    MAbs; 2015; 7(3):470-82. PubMed ID: 25774965
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Functional and molecular characterization of human monoclonal antibody reactive with the immunodominant region of HIV type 1 glycoprotein 41.
    Cavacini LA; Emes CL; Wisnewski AV; Power J; Lewis G; Montefiori D; Posner MR
    AIDS Res Hum Retroviruses; 1998 Sep; 14(14):1271-80. PubMed ID: 9764911
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bispecific molecules directed to the Fc receptor for IgA (Fc alpha RI, CD89) and tumor antigens efficiently promote cell-mediated cytotoxicity of tumor targets in whole blood.
    Deo YM; Sundarapandiyan K; Keler T; Wallace PK; Graziano RF
    J Immunol; 1998 Feb; 160(4):1677-86. PubMed ID: 9469424
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human single-chain antibodies inhibit replication of human immunodeficiency virus type 1 (HIV-1).
    Liu F; Kumar M; Ma Q; Duval M; Kuhrt D; Junghans R; Posner M; Cavacini L
    AIDS Res Hum Retroviruses; 2005 Oct; 21(10):876-81. PubMed ID: 16225415
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhancing natural killer cell function with gp41-targeting bispecific antibodies to combat HIV infection.
    Ramadoss NS; Zhao NQ; Richardson BA; Grant PM; Kim PS; Blish CA
    AIDS; 2020 Jul; 34(9):1313-1323. PubMed ID: 32287071
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Conformational Epitope-Specific Broadly Neutralizing Plasma Antibodies Obtained from an HIV-1 Clade C-Infected Elite Neutralizer Mediate Autologous Virus Escape through Mutations in the V1 Loop.
    Patil S; Kumar R; Deshpande S; Samal S; Shrivastava T; Boliar S; Bansal M; Chaudhary NK; Srikrishnan AK; Murugavel KG; Solomon S; Simek M; Koff WC; Goyal R; Chakrabarti BK; Bhattacharya J
    J Virol; 2016 Jan; 90(7):3446-57. PubMed ID: 26763999
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nanocell targeting using engineered bispecific antibodies.
    Taylor K; Howard CB; Jones ML; Sedliarou I; MacDiarmid J; Brahmbhatt H; Munro TP; Mahler SM
    MAbs; 2015; 7(1):53-65. PubMed ID: 25523746
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preclinical studies combining bispecific antibodies with cytokine-stimulated effector cells for immunotherapy of renal cell carcinoma.
    Elsässer D; Stadick H; Stark S; Van de Winkel JG; Gramatzki M; Schrott KM; Valerius T; Schafhauser W
    Anticancer Res; 1999; 19(2C):1525-8. PubMed ID: 10365137
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Unexpected recombinations in single chain bispecific anti-CD3-anti-CD33 antibodies can be avoided by a novel linker module.
    Stamova S; Cartellieri M; Feldmann A; Arndt C; Koristka S; Bartsch H; Bippes CC; Wehner R; Schmitz M; von Bonin M; Bornhäuser M; Ehninger G; Bachmann M
    Mol Immunol; 2011 Dec; 49(3):474-82. PubMed ID: 22014687
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rearranging the domain order of a diabody-based IgG-like bispecific antibody enhances its antitumor activity and improves its degradation resistance and pharmacokinetics.
    Asano R; Shimomura I; Konno S; Ito A; Masakari Y; Orimo R; Taki S; Arai K; Ogata H; Okada M; Furumoto S; Onitsuka M; Omasa T; Hayashi H; Katayose Y; Unno M; Kudo T; Umetsu M; Kumagai I
    MAbs; 2014; 6(5):1243-54. PubMed ID: 25517309
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HIV-1 Antibody Neutralization Breadth Is Associated with Enhanced HIV-Specific CD4+ T Cell Responses.
    Ranasinghe S; Soghoian DZ; Lindqvist M; Ghebremichael M; Donaghey F; Carrington M; Seaman MS; Kaufmann DE; Walker BD; Porichis F
    J Virol; 2015 Dec; 90(5):2208-20. PubMed ID: 26656715
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Engineering a CD123xCD3 bispecific scFv immunofusion for the treatment of leukemia and elimination of leukemia stem cells.
    Kuo SR; Wong L; Liu JS
    Protein Eng Des Sel; 2012 Oct; 25(10):561-9. PubMed ID: 22740616
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dual-Affinity Re-Targeting proteins direct T cell-mediated cytolysis of latently HIV-infected cells.
    Sung JA; Pickeral J; Liu L; Stanfield-Oakley SA; Lam CY; Garrido C; Pollara J; LaBranche C; Bonsignori M; Moody MA; Yang Y; Parks R; Archin N; Allard B; Kirchherr J; Kuruc JD; Gay CL; Cohen MS; Ochsenbauer C; Soderberg K; Liao HX; Montefiori D; Moore P; Johnson S; Koenig S; Haynes BF; Nordstrom JL; Margolis DM; Ferrari G
    J Clin Invest; 2015 Nov; 125(11):4077-90. PubMed ID: 26413868
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effective targeting of pathogens to neutrophils via chimeric surfactant protein D/anti-CD89 protein.
    Tacken PJ; Hartshorn KL; White MR; van Kooten C; van de Winkel JG; Reid KB; Batenburg JJ
    J Immunol; 2004 Apr; 172(8):4934-40. PubMed ID: 15067073
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Insertion of scFv into the hinge domain of full-length IgG1 monoclonal antibody results in tetravalent bispecific molecule with robust properties.
    Bezabeh B; Fleming R; Fazenbaker C; Zhong H; Coffman K; Yu XQ; Leow CC; Gibson N; Wilson S; Stover CK; Wu H; Gao C; Dimasi N
    MAbs; 2017; 9(2):240-256. PubMed ID: 27981887
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.